Table 2.
(A) tRNA scoring system implemented in HmtVar according to Yarham and Diroma criteria. The conservation criteria were modified thanks to the availability of Phastcons (31) and Phylop (32). (B) tRNA variant attributes to be considered for future improved disease score estimation
| A | tRNA Scoring Criteria | Yes | No | Yes Normalized |
|---|---|---|---|---|
| tRNA structure parameters and reports | ||||
| Variant described as pathogenic by more than 1 report | 2 | 0 | 0.1 | |
| Frequency and population data | ||||
| PhastCons conservation | 1 | 0 | 0.05 | |
| PhyloP conservation | 1 | 0 | 0.05 | |
| Variant Heteroplasmy | ||||
| Heteroplasmy evidences | 2 | 0 | 0.1 | |
| Evidences from functional studies | ||||
| Segregation of mutation with disease | 2 | 0 | 0.1 | |
| Histochemical evidence of mitochondrial disease | 2 | 0 | 0.1 | |
| Biochemical defect in OXPHOS complexes I, III or IV | 2 | 0 | 0.1 | |
| Pathogenicity evidence in trans mitochondrial cybrids or mutant mt-tRNA steady state level studies | 5 | 0 | 0.25 | |
| Evidence of mutation segregation with biochemical defect from single-fiber studies | 3 | 0 | 0.15 | |
| B | Additional tRNA variants Scoring Criteria | |||
| tRNA structure parameters and reports | ||||
| Cloverleaf-shaped secondary structure variation | ||||
| Post-transcriptional modification | ||||
| 3D interaction involved in folding | ||||
| Frequency and population data | ||||
| Allele variant frequency > 2% | ||||
| Allele variant frequency in patients > allele variant frequency in healthy individuals | ||||
| Macrohaplogroup-defining variant | ||||